Verteporfin, a benzo porphyrin derivative, evidenced anti-AML by targeting canonical NF-κB—activated in AML stem cells—which is essential for maintenance of the renewal of leukemia stem cells (LSCs). The gene discussed is NFKB1; the disease is acute myeloid leukemia.